United Capital Financial Advisors LLC Acquires New Shares in Insulet Corporation $PODD

United Capital Financial Advisors LLC bought a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the second quarter, Holdings Channel.com reports. The fund bought 8,086 shares of the medical instruments supplier’s stock, valued at approximately $1,231,000.

A number of other large investors have also recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of Insulet during the 2nd quarter valued at $1,018,582,000. Norges Bank purchased a new position in Insulet during the 4th quarter valued at about $300,794,000. Arrowstreet Capital Limited Partnership increased its position in shares of Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after buying an additional 1,011,369 shares during the period. Man Group plc bought a new stake in shares of Insulet during the second quarter valued at about $78,746,000. Finally, Bank of America Corp DE purchased a new stake in shares of Insulet in the second quarter worth about $64,921,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on PODD shares. The Goldman Sachs Group reaffirmed a “buy” rating and set a $205.00 price objective on shares of Insulet in a research note on Wednesday, May 27th. TD Cowen lowered their price objective on Insulet from $294.00 to $144.00 and set a “hold” rating on the stock in a research report on Thursday, August 6th. Bank of America dropped their price objective on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Stifel Nicolaus reduced their target price on Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Finally, Royal Bank Of Canada lowered their price target on Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $195.40.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s latest reported quarter showed strong fundamentals: revenue rose 23.5% year over year to $801.7 million, while adjusted earnings of $1.66 per share exceeded the $1.47 analyst consensus. The company has also issued fiscal 2026 earnings guidance, with analysts projecting approximately $6.51 per share. Insulet financial and trading information
• Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, and Robbins Geller—reminded investors that August 31, 2026 is the deadline to seek lead-plaintiff status in the securities class action. The notices generally cover purchases made between February 21, 2025 and May 26, 2026, although one complaint cites a later starting date of May 21, 2025. Rosen Insulet deadline notice
• Negative Sentiment: The litigation creates an overhang because investors allege Insulet and certain officers violated federal securities laws and seek damages. The notices reference two Omnipod medical-device corrections and a decline of more than $90 per share from pre-disclosure levels, potentially increasing concerns about product quality, disclosure practices, legal costs, and reputational risk. The allegations have not been proven. Insulet investor litigation alert

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.36% of the stock is owned by insiders.

Insulet Trading Up 1.2%

NASDAQ PODD opened at $145.13 on Friday. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The stock’s 50-day simple moving average is $154.46 and its two-hundred day simple moving average is $181.15. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The company has a market capitalization of $10.06 billion, a price-to-earnings ratio of 27.13, a PEG ratio of 1.14 and a beta of 1.10.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company’s revenue was up 23.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Research analysts forecast that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.